We are a biotechnology company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat chronic energy balance disorders diseases in metabolically challenged elderly and/or obese individuals. Drugs that activate AMPK are expected to have beneficial effects on metabolic and cardiorenal diseases. Our lead first-in-class PAN-AMPK activator O304 has successfully completed an exploratory 28 day phase IIa clinical trial in patients with type 2 diabetes on metformin.
The preclinical and most of the phase IIA results with O304 have been published in JCI insight as an article entitled:
”PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients”.
View the article here: https://insight.jci.org/articles/view/99114
O304 also shows beneficial hemodynamic effects on kidney filtration in type 2 diabetes patients:
”AMPK activator O304 – a novel treatment for Type 2 diabetes and diabetic kidney disease
View the article here: https://www.healtheuropa.eu/ampk-O304-diabetic-kidney-disease/86703/